Saha, Debanjan
Dang, Ha X. http://orcid.org/0000-0002-9342-9249
Zhang, Meng http://orcid.org/0000-0003-1042-6294
Quigley, David A. http://orcid.org/0000-0002-4726-1473
Feng, Felix Y. http://orcid.org/0000-0002-0963-7687
Maher, Christopher A. http://orcid.org/0000-0002-9035-603X
Funding for this research was provided by:
Prostate Cancer Foundation
U.S. Department of Defense (W81XWH-19-1-0682)
Article History
Received: 3 August 2023
Accepted: 7 February 2024
First Online: 23 February 2024
Competing interests
: F.Y.F. reports personal fees from Janssen Oncology, Bayer, PFS Genomics, Myovant Sciences, Roivant Sciences, Astellas Pharma, Foundation Medicine, Varian, Bristol Myers Squibb (BMS), Exact Sciences, BlueStar Genomics, Novartis, and Tempus; other support from Serimmune and Artera outside the submitted work. CAM reports licensing income from Tempus.